Bimosiamose
CAS: 187269-40-5
Rif. 3D-MHA26940
1mg | Fuori produzione | ||
5mg | Fuori produzione | ||
10mg | Fuori produzione | ||
25mg | Fuori produzione | ||
50mg | Fuori produzione |
Informazioni sul prodotto
- (1,1'-Biphenyl)-3-acetic acid, 3',3'''-(1,6-hexanediyl)bis(6'-(alpha-D-mannopyranosyloxy)-
- (Hexane-1,6-diylbis(6'-(alpha-D-mannopyranosyloxy)biphenyl-3',3-diyl))diacetic acid
- 1,6-Bis(3-(3-carboxymethylphenyl)-4-(2-alpha-D-mannopyranosyloxy)phenyl)hexane
- 3′,3′′′-(1,6-Hexanediyl)bis[6′-(α-<span class="text-smallcaps">D</span>-mannopyranosyloxy)[1,1′-biphenyl]-3-acetic acid
- Tbc 1269
- Unii-97B5Kcw80W
- [1,1′-Biphenyl]-3-acetic acid, 3′,3′′′-(1,6-hexanediyl)bis[6′-(α-<span class="text-smallcaps">D</span>-mannopyranosyloxy)-
- [1,1′-Biphenyl]-3-acetic acid, 3′,3′′′-(1,6-hexanediyl)bis[6′-(α-D-mannopyranosyloxy)-
- 3′,3′′′-(1,6-Hexanediyl)bis[6′-(α-D-mannopyranosyloxy)[1,1′-biphenyl]-3-acetic acid
Bimosiamose is a metabolite of the biotin-dependent enzyme, methionine adenosyltransferase. It is an activated form of SAMe and has been shown to have beneficial effects in treating patients with metabolic disorders. Bimosiamose also has anti-inflammatory properties and can be used as an adjunct therapy for bowel disease. In vitro studies have shown that bimosiamose inhibits the activity of monoclonal antibodies that bind to the CD20 receptor on hl-60 cells, which causes these cells to die by apoptosis. This compound is also able to inhibit the production of inflammatory cytokines, such as IL-6 and TNF-α, in vitro.